

# Laura Russo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7190052/publications.pdf>

Version: 2024-02-01

34  
papers

1,501  
citations

394421

19  
h-index

477307

29  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1873  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms and risk factors of thrombosis in cancer. Critical Reviews in Oncology/Hematology, 2017, 118, 79-83.	4.4	183
2	V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Experimental Hematology, 2007, 35, 702-711.	0.4	169
3	Procoagulant mechanisms in tumour cells. Best Practice and Research in Clinical Haematology, 2009, 22, 49-60.	1.7	146
4	The mechanisms of cancer-associated thrombosis. Thrombosis Research, 2015, 135, S8-S11.	1.7	114
5	Mechanisms of thrombosis in cancer. Thrombosis Research, 2013, 131, S59-S62.	1.7	94
6	Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thrombosis Research, 2008, 121, 637-645.	1.7	80
7	Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. American Journal of Hematology, 2011, 86, 337-342.	4.1	78
8	The coagulopathy of cancer. Current Opinion in Hematology, 2014, 21, 423-429.	2.5	74
9	JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood, 2011, 118, 2599-2601.	1.4	61
10	Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients. Cancer Treatment and Research, 2019, 179, 11-36.	0.5	56
11	Venous thromboembolism in the hematologic malignancies. Current Opinion in Oncology, 2012, 24, 702-710.	2.4	55
12	Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. American Journal of Hematology, 2014, 89, 68-73.	4.1	53
13	Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 2010, 104, 151-156.	3.4	51
14	ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. Thrombosis Research, 2013, 132, 88-93.	1.7	41
15	PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011068.	1.3	29
16	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. Thrombosis Research, 2016, 140, S55-S59.	1.7	29
17	Clinical characteristics and genetic analysis in women with premature ovarian insufficiency. Maturitas, 2013, 74, 61-67.	2.4	27
18	LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells. Cancer Investigation, 2011, 29, 153-161.	1.3	24

#	ARTICLE	IF	CITATIONS
19	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. Haematologica, 2020, 105, 1704-1711.	3.5	21
20	Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies. Thrombosis and Haemostasis, 2012, 107, 468-476.	3.4	17
21	Thrombin generation predicts early recurrence in breast cancer patients. Journal of Thrombosis and Haemostasis, 2020, 18, 2220-2231.	3.8	17
22	All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells. Thrombosis Research, 2011, 128, 368-374.	1.7	15
23	Long Term Low Molecular Weight Heparin Anticoagulant Therapy Modulates Thrombin Generation and D-dimer in Patients with Cancer and Venous Thromboembolism. Cancer Investigation, 2017, 35, 490-499.	1.3	13
24	Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. Journal of the American Academy of Dermatology, 2016, 74, 1254-1256.e4.	1.2	9
25	Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. TH Open, 2021, 05, e56-e65.	1.4	9
26	Exacerbation of Autoimmune Thyroiditis Following Bilateral Adrenalectomy for Cushing's Syndrome. Thyroid, 2010, 20, 669-670.	4.5	8
27	Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand?. Seminars in Thrombosis and Hemostasis, 2021, 47, 962-971.	2.7	8
28	Platelet haemostatic properties in $\beta^2$ -thalassaemia: the effect of blood transfusion. Blood Transfusion, 2017, 15, 413-421.	0.4	8
29	Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	6
30	APL Coagulopathy. , 2018, , 55-70.		3
31	Mechanisms of Thrombogenesis. , 2012, , 57-67.		2
32	Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. Blood Transfusion, 2021, , .	0.4	1
33	Response to Niepomniszcz and Pitoia. Thyroid, 2011, 21, 208-208.	4.5	0
34	Hemostatic system activation in breast cancer: Searching for new biomarkers for cancer risk prediction and outcomes. Thrombosis Research, 2022, 213, S46-S50.	1.7	0